Apotex India

Apotex India company information, Employees & Contact Information

Explore related pages

Related company profiles:

Apotex is a proudly Canadian, global pharmaceutical company with a presence in India consisting of Apotex Research Private Limited (ARPL), an affiliate of Apotex that operates in Mumbai and Bangalore, Apotex Pharmachem India Pvt Ltd (APIPL) in Bangalore, and Global Business Services (GBS), Apotex’s captive service delivery organization in Mumbai. Founded in 2004, ARPL holds expertise in the development of both generic and innovative pharmaceuticals, quality and regulatory control mechanisms, manufacturing, site transfers, bio equivalence, and clinical research. ARPL's manufacturing facility in Bangalore has been designed to support an annual output capacity of over eight billion dosages. APIPL operates a fully CGMP-compliant manufacturing facility specializing in the research and development, scale-up and manufacturing of active pharmaceutical ingredients (API), and has two multi-purpose manufacturing plants and three kilo labs. GBS operates under global policies and procedures, supporting 33 business processes across 7 functions of Apotex. Committed to excellence and focused on continuous improvement, guiding GBS is its vision to be a best-in-class service delivery function. In 2022, Apotex India was awarded the 2nd Best Place to Work in India by AmbitionBox, India's largest employee choice awards and the most popular platform for company reviews.

Company Details

Employees
987
Address
Jigani Link Road, Bangalore,karnataka 560099,india
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
(GBS).
HQ
Bangalore, Karnataka
Looking for a particular Apotex India employee's phone or email?

Apotex India Questions

News

Apotex Receives Health Canada Approval for LOQTORZI® — The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer - Cantech Letter

Apotex Receives Health Canada Approval for LOQTORZI® — The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer Cantech Letter

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal - PR Newswire

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal PR Newswire

Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity - PR Newswire Canada

Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity PR Newswire Canada

Apotex receives Health Canada approval for Aflivutm, a biosimilar to Eylea®, available in pre-filled syringe and vial formats - Lelezard

Apotex receives Health Canada approval for Aflivutm, a biosimilar to Eylea®, available in pre-filled syringe and vial formats Lelezard

Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact - PR Newswire Canada

Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact PR Newswire Canada

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Business Wire

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products Business Wire

Apotex Eye Drops: Uses, Dosage, Side Effects & More - Consumer Notice

Apotex Eye Drops: Uses, Dosage, Side Effects & More Consumer Notice

Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States - PR Newswire

Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States PR Newswire

Apotex Corp. recalling nasal sprays due to potential for small glass particles - KCBD

Apotex Corp. recalling nasal sprays due to potential for small glass particles KCBD

Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil) - PR Newswire Canada

Apotex acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil) PR Newswire Canada

Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States - PR Newswire

Apotex Corp. is the first generic manufacturer to launch dasatinib tablets in the United States PR Newswire

Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company - PR Newswire Canada

Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company PR Newswire Canada

Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre - PR Newswire Canada

Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre PR Newswire Canada

Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment - PR Newswire Canada

Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment PR Newswire Canada

Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride) - PR Newswire Canada

Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing of the Canadian rights to SEYSARA® (sarecycline) and FINJUVE™ (finasteride) PR Newswire Canada

Apotex Inc. to Present at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference - PR Newswire Canada

Apotex Inc. to Present at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference PR Newswire Canada

Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology - PR Newswire Canada

Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology PR Newswire Canada

Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader - PR Newswire Canada

Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader PR Newswire Canada

Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company - PR Newswire Canada

Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company PR Newswire Canada

Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab - PR Newswire Canada

Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab PR Newswire Canada

SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals - PR Newswire Canada

SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals PR Newswire Canada

Apotex Corp. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, 28x3 blister pack/carton due to possibility of missing/incorrect tablet arrangement - PR Newswire

Apotex Corp. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, 28x3 blister pack/carton due to possibility of missing/incorrect tablet arrangement PR Newswire

Apotex Ofloxacin Otic Solution 0.3% Generic Version of Floxin Otic® Now Available - PR Newswire

Apotex Ofloxacin Otic Solution 0.3% Generic Version of Floxin Otic® Now Available PR Newswire

Birth Control Recall After Packaging Error - Newsweek

Birth Control Recall After Packaging Error Newsweek

Nasal spray recalled due to glass particles - WXYZ Channel 7

Nasal spray recalled due to glass particles WXYZ Channel 7

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant